Topiramate compositions and methods of enhancing its bioavailability
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/22
A61K-009/28
A61K-009/16
A61K-009/20
A61K-009/48
A61K-009/50
A61K-031/357
출원번호
US-0897940
(2007-08-31)
등록번호
US-9744137
(2017-08-29)
발명자
/ 주소
Nangia, Avinash
Verma, Daya D.
Jacob, Jules
출원인 / 주소
Supernus Pharmaceuticals, Inc.
대리인 / 주소
Talapatra, Sunit
인용정보
피인용 횟수 :
0인용 특허 :
62
초록▼
The present invention is directed to pharmaceutical compositions that allow for once-daily or alternate day dosage forms of topiramate. The proposed delayed/extended release single dosage form is equivalent to the immediate-release multiple dose daily regimen, and upon administration, provides stead
The present invention is directed to pharmaceutical compositions that allow for once-daily or alternate day dosage forms of topiramate. The proposed delayed/extended release single dosage form is equivalent to the immediate-release multiple dose daily regimen, and upon administration, provides steady state blood levels of topiramate. Formulations with increased bioavailability and improved pharmacokinetics are disclosed. A once-a-day administration of topiramate is advantageous over the multiple dose regimen both in terms of patient compliance and reduced adverse events, thus providing better treatment of the conditions for which the topiramate is indicated.
대표청구항▼
1. A delayed-release oral pharmaceutical composition, comprising: (a) only one active agent, the active agent being selected from the group consisting of topiramate and pharmaceutically acceptable salts thereof,(b) particles having a core formulated as a matrix comprising the active agent coated wit
1. A delayed-release oral pharmaceutical composition, comprising: (a) only one active agent, the active agent being selected from the group consisting of topiramate and pharmaceutically acceptable salts thereof,(b) particles having a core formulated as a matrix comprising the active agent coated with an enteric polymer coatingor particles having a core coated with a layer comprising the active agent, and further coated with an enteric polymer coating,wherein the enteric polymer coating becomes soluble at a pH above 4.5 and delays the release of topiramate about 0.5 to about 4 hours. 2. The composition of claim 1, further comprising a release-controlling polymer selected from the group consisting of ammonio methacrylate copolymer, types A and B; ethylcellulose aqueous dispersions, hydroxyethyl cellulose, cellulose acetate, cellulose acetate butyrate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, and any combination thereof. 3. The composition of claim 1, wherein the composition comprises two or more cores. 4. The composition of claim 3, wherein at least one core is formulated for immediate release (IR). 5. The composition of claim 3, wherein at least one core comprises a release-controlling polymer. 6. The composition of claim 3, comprising a first immediate release core and a second core coated with a release-controlling polymer. 7. The composition of claim 6, wherein the release-controlling polymer is selected from ammonio methacrylate copolymer, types A and B; ethylcellulose aqueous dispersions, hydroxyethyl cellulose, cellulose acetate, cellulose acetate butyrate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, or any combination thereof. 8. The composition of claim 1, wherein the enteric coating is selected from cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, copolymer of methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate, methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic anhydride, ethyl methyacrylate-methylmethacrylate-chlorotrimethylammonium ethyl acrylate copolymer, natural resins, carboxymethyl ethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters, or any combination thereof. 9. The composition of claim 1, wherein the composition comprises micronized topiramate having a median particle size in the range of 1-250 microns. 10. The composition of claim 1, further comprising at least one basifying agent. 11. The composition of claim 1, further comprising a least one surfactant or co-surfactant. 12. The composition of claim 1 for once-a-day administration. 13. The composition of claim 1, wherein the matrix further comprises at least one pharmaceutically acceptable excipient selected from a group consisting of binding agents, bulking agents, and disintegrants. 14. The composition of claim 1, wherein at least one core is coated with an IR layer. 15. The composition of claim 1, wherein at least one core is coated with an extended release (XR) layer. 16. The composition of claim 3, wherein a first core is an immediate release core and a second core is coated with a release-controlling polymer. 17. The composition of claim 15, wherein the XR layer comprises a release-controlling polymer selected from the group consisting of ammonio methacrylate copolymer, types A and B; ethylcellulose aqueous dispersions, hydroxyethyl cellulose, cellulose acetate, cellulose acetate butyrate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, and any combination thereof. 18. The composition of claim 1, wherein the particles are encapsulated in a gelatin capsule. 19. The composition of claim 1, wherein the particles are multiparticulate beads or pellets. 20. The composition of claim 19, wherein the multiparticulate beads or pellets are encapsulated in a gelatin capsule. 21. The composition of claim 1, wherein the Cmax produced by dosing the composition in vivo is higher by about 20% to about 80% of the Cmax of the same amount of topiramate administered as an immediate release composition. 22. The composition of claim 1, wherein the AUC produced by dosing the composition in vivo is higher by about 70% to about 140% of the AUC of the same amount of topiramate administered as an immediate release composition. 23. The composition of claim 1, wherein the weight of the enteric polymer coating is about 7% to about 13% of the weight of the composition. 24. The composition of claim 1, wherein the topiramate or a pharmaceutically acceptable salt thereof is present in an amount of about 15 mg to about 400 mg. 25. The composition of claim 8, wherein the natural resin is zein, shellac, or copal collophorium.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (62)
Cottrell Sandra C., Anticonvulsant derivatives useful in lowering blood pressure.
Dunn Richard L. (451 Boardwalk Dr. RLD ; Apt. 501 Fort Collins CO 80526) English James P. (2500 Melinda Cir. Birmingham AL 35214) Cowsar Donald R. (4657 Round Forest Dr. Birmingham AL 35213) Vanderbi, Biodegradable in-situ forming implants and methods of producing the same.
Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use.
Lerner, E. Itzhak; Rosenberger, Vered; Aqua, Ofer; Fleshner Barak, Moshe, Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it.
Fleshner Barak,Moshe; Lerner,E. Itzhak; Rosenberger,Vered, Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery.
Sackler Richard (Greenwich CT) Goldenheim Paul (Wilton CT) Kaiko Robert (Weston CT), Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasm.
Santos Camila A. ; Jacob Jules S. ; Hertzog Benjamin A. ; Carino Gerardo P. ; Mathiowitz Edith, Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients.
Santos Camila A. ; Jacob Jules S. ; Hertzog Benjamin A. ; Carino Gerardo P. ; Mathiowitz Edith, Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients.
Joshi Yatindra M. (Piscataway NJ) Chiesa Pierina (South Orange NJ) Jain Nemichand B. (Monmouth Junction NJ), Pharmaceutical compositions having good stability.
Joshi Yatindra M. (Piscataway NJ) Chiesa Pierina (South Orange NJ) Jain Nemichand B. (Monmouth Junction NJ), Pravastatin pharmaceuatical compositions having good stability.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.